Overview

Cell Viability Assays Market Introduction:

Cell Viability Assays Market is estimated to value over USD 5.1 billion by 2027 end and register CAGR of over 8% by 2027 end.

Cell viability assays are technologies that are used for determining the cell strength in response to any tested drug. They are generally tested on a tissue, cell or an organ. Cell viability looks for the cells to identify any inorganic reaction which they aren’t supposed to follow and scale this reaction to mark its viability. This plays an important role in all forms of cell culture. Cell viability forms the basis of an assay to look out for drug effectiveness or cell viability with multiple combined particles and it also offers different characteristics of cell health to the user.

Cell viability assay is primarily performed in all in vitro and pharmaceutical studies due to increased applications of cell viability assays for drug screening. A large number of local manufacturers have expanded their cell viability assay kits product portfolio to determine effects in cell growth and cell death for the sake of clinical research and this has increased the demand for cell viability assays thus aiding the cell viability assays market size proliferation.

Key market players include:
Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton, Dickinson and Company, Promega Corporation, Biotium, Abcam PLC, Creative Bioarray, Biotek Instruments, Perkinelmer.

Cell Viability Assays Market Segmentation:

By Product

• Consumables
• Reagents
• Assay Kits
• Tetrazolium Reduction Assay Kits
• Mtt Assay Kits
• Other Tetrazolium Assay Kits
• Resazurin Cell Viability Assay Kits
• Calcein-Am Cell Viability Assay Kits
• Other Assay Kits
• Microplates
• Instruments
• Automated Cell Counters
• Flow Cytometers
• Spectrophometers
• Cell Imaging & Analysis Systems

 By Cell Type

• Human Cells
• Animal Cells
• Microbial Cells

By Application

• Drug Discovery and Development
• Basic Research
• Stem Cell Research
• Clinical and Diagnostic Applications
• Other Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Diagnostic Laboratories
• Other End Users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share 
• Tier 2 players 
• Emerging players which are growing rapidly 
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global cell viability assays market by product, by cell type, by application, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
        1.1. Objectives of the Study 
        1.2. Market Definition 
        1.3. Market Scope 
               1.3.1. Years Considered for the Study
               1.3.2. Market Covered
        1.4. Currency 
        1.5. Limitations 
        1.6. Stakeholders 
 2.  Research Methodology 
        2.1. Research Data 
               2.1.1. Secondary Data
                          2.1.1.1. Key Data from Secondary Sources
               2.1.2. Primary Data
                          2.1.2.1. Key Data from Primary Sources
        2.2. Market Size Estimation 
        2.3. Market Breakdown and Data Triangulation 
        2.4. Assumptions for the Study  
3. Executive Summary
        3.1. Market Outlook
        3.2. Segment Outlook
        3.3. Competitive Insights
4. Global Cell Viability Assays Market Variables, Trends & Scope
        4.1. Market Lineage Outlook
        4.2. Penetration and Growth Prospect Mapping
        4.3. Industry Value Chain Analysis
        4.4. Cost Analysis Breakdown
        4.5. Technology Overview
        4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Cell Viability Assays Market Overview
        5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Cell Viability Assays Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Cell Viability Assays Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
        6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
        6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
        6.4. Market Entry Strategies
        6.5. Case Studies
7. Global Cell Viability Assays Market, By Product Historical Analysis and Forecast 2020-2027 (USD Million)
        7.1 Consumables
           7.1.1. Reagents
               7.1.2. Assay Kits
                          7.1.2.1. Tetrazolium Reduction Assay Kits
                                         7.1.2.1.1. Mtt Assay Kits
                                          7.1.2.1.2. Other Tetrazolium Assay Kits
                          7.1.2.2. Resazurin Cell Viability Assay Kits
                          7.1.2.3. Calcein-Am Cell Viability Assay Kits
                          7.1.2.4. Other Assay Kits
               7.1.3. Microplates
       7.2. Instruments
               7.2.1. Automated Cell Counters
               7.2.2. Flow Cytometers
               7.2.3. Spectrophometers
               7.2.4. Cell Imaging & Analysis Systems
8. Global Cell Viability Assays Market, By Cell Type Historical Analysis and Forecast 2020-2027 (USD Million)
        8.1 Human Cells
        8.2 Animal Cells
        8.3 Microbial Cells
9. Global Cell Viability Assays Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
        9.1 Drug Discovery and Development
        9.2 Basic Research
        9.3 Stem Cell Research
        9.4 Clinical and Diagnostic Applications
        9.5 Other Applications
10. Global Cell Viability Assays Market, By End-User Historical Analysis and Forecast 2020-2027 (USD Million)
        10.1. Pharmaceutical & Biotechnology Companies
        10.2. Academic & Research Institutes
        10.3. Hospital & Diagnostic Laboratories
        10.4. Other End Users
11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        11.1. Introduction
        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  11.2.1. U.S.A
                  11.2.2. Canada
                  11.2.3. Mexico
        11.3. Market Size (USD Million) Forecast for North America 2020-2027 
12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        12.1. Introduction
        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                 12.2.1. Brazil
                 12.2.2. Venezuela
                 12.2.3. Argentina
                 12.2.4. Rest of Latin America
        12.3. Market Size (USD Million) Forecast for Latin America 2020-2027  
13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        13.1. Introduction
        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  13.2.1. Germany
                  13.2.2. U.K
                  13.2.3. France
                  13.2.4. Italy
                  13.2.5. Spain
                  13.2.6. Russia
                  13.2.7. Poland
                  13.2.8. Rest of Europe
        13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        14.1. Introduction
        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  14.2.1. Japan
                  14.2.2. China
                  14.2.3. India
                  14.2.4. Australia and New Zealand
                  14.2.5. ASEAN
                  14.2.6. Rest of Asia Pacific
        14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        15.1. Introduction
        15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  15.2.1. Saudi Arabia
                  15.2.2. UAE
                  15.2.3. South Africa
                  15.2.4. Egypt
        15.3. Market Size (USD Million) Forecast for MEA 2020-2027           
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    16.1 Thermo Fisher Scientific
            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.1.2. Product Portfolio
            16.1.3. SWOT Analysis
            16.1.4. Financial Overview
            16.1.5. Strategic Overview
    16.2 Merck KGaA
            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.2.2. Product Portfolio
            16.2.3. SWOT Analysis
            16.2.4. Financial Overview
            16.2.5. Strategic Overview
    16.3 Bio-Rad Laboratories
            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2. Product Portfolio
            16.3.3. SWOT Analysis
            16.3.4. Financial Overview
            16.3.5. Strategic Overview
    16.4 GE Healthcare
            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.4.2. Product Portfolio
            16.4.3. SWOT Analysis
            16.4.4. Financial Overview
            16.4.5. Strategic Overview
    16.5 Danaher Corporation
            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.5.2. Product Portfolio
            16.5.3. SWOT Analysis
            16.5.4. Financial Overview
            16.5.5. Strategic Overview
    16.6  Becton
            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.6.2. Product Portfolio
            16.6.3. SWOT Analysis
            16.6.4. Financial Overview
            16.6.5. Strategic Overview
    16.7 Dickinson and Company
            16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.7.2. Product Portfolio
            16.7.3. SWOT Analysis
            16.7.4. Financial Overview
            16.7.5. Strategic Overview
    16.8 Promega Corporation
            16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.8.2. Product Portfolio
            16.8.3. SWOT Analysis
            16.8.4. Financial Overview
            16.8.5. Strategic Overview
    16.9 Biotium
            16.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.9.2. Product Portfolio
            16.9.3. SWOT Analysis
            16.9.4. Financial Overview
            16.9.5. Strategic Overview
    16.10 Abcam PLC
            16.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.10.2. Product Portfolio
            16.10.3. SWOT Analysis
            16.10.4. Financial Overview
            16.10.5. Strategic Overview
    16.11  Creative Bioarray
            16.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.11.2. Product Portfolio
            16.11.3. SWOT Analysis
            16.11.4. Financial Overview
            16.11.5. Strategic Overview
    16.12 Biotek Instruments
            16.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.12.2. Product Portfolio
            16.12.3. SWOT Analysis
            16.12.4. Financial Overview
            16.12.5. Strategic Overview
    16.13 Perkinelmer
            16.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.13.2. Product Portfolio
            16.13.3. SWOT Analysis
            16.13.4. Financial Overview
            16.13.5. Strategic Overview
17. FutureWise SME Key Takeaway Points for Client

Tables

Figures